Effect of 3α-dihydroprogesterone and 5α-dihydroprogesterone on DCIS cells and possible impact for postmenopausal women

References

• Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Trans Med Chir Soc Edinb. 1896;15:153–179.
   PubMedGoogle Scholar
• Zbuk K, Anand SS. Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. J Epidemiol Community Health. 2012;66(1):1–7.
   PubMed Web of Science ®Google Scholar
• Wiebe JP, Muzia D, Hu J, et al. The 4-pregnene and 5alpha-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Res. 2000;60(4):936–943.
   PubMed Web of Science ®Google Scholar
• Wiebe JP, Beausoleil M, Zhang G, et al. Opposing actions of the progesterone metabolites, 5alpha-dihydroprogesterone (5alphaP) and 3alpha-dihydroprogesterone (3alphaHP) on mitosis, apoptosis, and expression of Bcl-2, Bax and p21 in human breast cell lines. J Steroid Biochem Mol Biol. 2010;118(1–2):125–132.
   PubMed Web of Science ®Google Scholar
• Poole AJ, Li Y, Kim Y, et al. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science. 2006;314(5804):1467–1470.
   PubMed Web of Science ®Google Scholar
• Trabert B, Sherman ME, Kannan N, et al. Progesterone and breast cancer. Endocr Rev. 2020;41(2):320–344.
   PubMed Web of Science ®Google Scholar
• Hewitt SC, Korach KS. Progesterone action and responses in the alphaERKO mouse. Steroids. 2000;65(10–11):551–557.
   PubMed Web of Science ®Google Scholar
• Treeck O, Schüler-Toprak S, Ortmann O. Estrogen actions in triple-negative breast cancer. Cells. 2020;9(11):2358.
   PubMed Web of Science ®Google Scholar
• Wiebe JP, Muzia D, Hu J, et al. The 4-pregnene and 5α-pregnane progesterone metabolites formed in non-tumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Research. 2000;60:936–943.
   PubMed Web of Science ®Google Scholar
• Wiebe JP, Lewis MJ. Activity and expression of progesterone metabolizing 5α-reductase, 20α-hydroxysteroid oxidoreductase and 3α(β)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells. BMC Cancer. 2003;3:9.
   PubMed Web of Science ®Google Scholar
• Wiebe JP. Progesterone metabolites in breast cancer. Endocr Relat Cancer. 2006;13(3):717–738.
   PubMed Web of Science ®Google Scholar
• Pawlak KJ, Zhang G, Wiebe JP. Membrane 5alpha-pregnane-3,20-dione (5alphaP) receptors in MCF-7 and MCF-10A breast cancer cells are up-regulated by estradiol and 5alphaP and down-regulated by the progesterone metabolites, 3alpha-dihydroprogesterone and 20alpha-dihydroprogesterone, with associated changes in cell proliferation and detachment. J Steroid Biochem Mol Biol. 2005;97(3):278–288.
   PubMed Web of Science ®Google Scholar
• Kumar P, Magon N. Hormones in pregnancy. Niger Med J. 2012;53(4):179–183.
   PubMedGoogle Scholar
• Zubeldia-Brenner L, Roselli CE, Recabarren SE, et al. Developmental and functional effects of steroid hormones on the neuroendocrine axis and spinal cord. J Neuroendocrinol. 2016;28(7):12401.
   Web of Science ®Google Scholar
• Dressing GE, Goldberg JE, Charles NJ, et al. Membrane progesterone receptor expression in mammalian tissues: a review of regulation and physiological implications. Steroids. 2011;76(1–2):11–17.
   PubMed Web of Science ®Google Scholar
• Singh M, Su C, Ng S. Non-genomic mechanisms of progesterone action in the brain. Front Neurosci. 2013;7:159.
   PubMed Web of Science ®Google Scholar
• Ismail PM, Li J, DeMayo FJ, et al. A novel LacZ reporter mouse reveals complex regulation of the progesterone receptor promoter during mammary gland development. Mol Endocrinol. 2002;16(11):2475–2489.
   PubMedGoogle Scholar
• Rajaram RD, Brisken C. Paracrine signaling by progesterone. Mol Cell Endocrinol. 2012;357(1–2):80–90.
   PubMed Web of Science ®Google Scholar
• Tanos T, Sflomos G, Echeverria PC, et al. Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med. 2013;5(182):182ra155.
   Web of Science ®Google Scholar
• Ruan X, Gu M, Cai G, et al. Progestogens and PGRMC1-dependent breast cancer tumor growth: an in-vitro and xenograft study. Maturitas. 2019;123:1–8.
   PubMed Web of Science ®Google Scholar
• Kuhl H, Schneider HPG. Progesterone – promoter or inhibitor of breast cancer. Climacteric. 2013;16(sup1):54–68.
   PubMed Web of Science ®Google Scholar
• Tian JM, Ran B, Zhang CL, et al. Estrogen and progesterone promote breast cancer cell proliferation by inducing cyclin G1 expression. Braz J Med Biol Res. 2018;51(3):1–7.
   PubMed Web of Science ®Google Scholar
• Lange CA, Yee D. Progesterone and breast cancer. Womens Health. 2008;4(2):151–162.
   Google Scholar
• Obr AE, Edwards DP. The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol. 2012;357(1–2):4–17.
   PubMed Web of Science ®Google Scholar
• Clarke RB, Howell A, Potten CS, et al. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 1997;57(22):4987–4991.
   PubMed Web of Science ®Google Scholar
• Gompel A, Malet C, Spritzer P, et al. Progestin effect on cell proliferation and 17 beta-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J Clin Endocrinol Metab. 1986;63(5):1174–1180.
   PubMed Web of Science ®Google Scholar
• Vogel PM, Georgiade NG, Fetter BF, et al. The correlation of histologic changes in the human breast with the menstrual cycle. Am J Pathol. 1981;104(1):23–34.
   PubMed Web of Science ®Google Scholar
• Going JJ, Anderson TJ, Battersby S, et al. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol. 1988;130(1):193–204.
   PubMed Web of Science ®Google Scholar
• Calle EE, Feigelson HS, Hildebrand JS, et al. Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer. 2009;115(5):936–945.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA. 2020;324(4):369–380.
   PubMed Web of Science ®Google Scholar
• Marjoribanks J, Farquhar C, Roberts H, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017;1(1):CD004143.
   PubMedGoogle Scholar
• Pardo I, Lillemoe HA, Blosser RJ, et al. Next-generation transcriptome sequencing of the premenopausal breast epithelium using specimens from a normal human breast tissue bank. Breast Cancer Res. 2014;16(2):R26.
   PubMed Web of Science ®Google Scholar
• Villanueva H, Grimm S, Dhamne S, et al. The emerging roles of steroid hormone receptors in ductal carcinoma in situ (DCIS) of the breast [published correction appears in J mammary gland biol neoplasia. J Mammary Gland Biol Neoplasia. 2018;23(4):237–248.
   PubMed Web of Science ®Google Scholar
• Luo J, Cochrane BB, Wactawski-Wende J, et al. Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2013;137(3):915–925.
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006;295(14):1647–1657.
   PubMed Web of Science ®Google Scholar
• Miller FR, Santner SJ, Tait L, et al. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst. 2000;92:1185–1186.
   PubMedGoogle Scholar
• Soule HD, Maloney TM, Wolman SR, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990;50(18):6075–6086.
   PubMed Web of Science ®Google Scholar
• Osuala KO, Sameni M, Shah S, et al. Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration. BMC Cancer. 2015;15(1):584.
   PubMedGoogle Scholar
• Lo PK, The controversial role of forkhead box F2 (FOXF2) transcription factor in breast cancer. PRAS Open. 2017;1:009.
   PubMedGoogle Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196.
   PubMed Web of Science ®Google Scholar
• Beavon IR. The E-cadherin–catenin complex in tumour metastasis. Eur J Cancer. 2000;36(13):1607–1620.
   PubMed Web of Science ®Google Scholar
• Allegra JC, Korat O, Do HM, et al. The regulation of progesterone receptor by 17 beta estradiol and tamoxifen in the Zr-75-1 human breast cancer cell line in defined medium. J Recept Res. 1981;2(1):17–27.
   PubMed Web of Science ®Google Scholar
• Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology. 1978;103(5):1742–1751.
   PubMed Web of Science ®Google Scholar
• Fu J, Weise AM, Falany JL, et al. Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression. Breast Cancer Res Treat. 2010;120(1):35–45.
   PubMed Web of Science ®Google Scholar
• Sourouni M, Kiesel L. Hormone replacement therapy after gynaecological malignancies: a review article. Geburtshilfe Frauenheilkd. 2021;81(5):549–554.
   PubMedGoogle Scholar
• Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) in Kooperation mit der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF). 2017. S3-Leitlinie: Peri-und Postmenopause – Diagnostik und Interventionen; [cited 2022 Jan 29]. Available from: https://www.awmf.org/uploads/tx_szleitlinien/015-062l_S3_KF_Peri-Postmenopause-Diagnostik-Intervention_2018-11.pdf.
   Google Scholar
• Brock EJ, Ji K, Shah S, et al. In vitro models for studying invasive transitions of ductal carcinoma in situ. J Mammary Gland Biol Neoplasia. 2019;24(1):1–15.
   PubMed Web of Science ®Google Scholar
• Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod. 2005;20(8):2052–2060.
   PubMed Web of Science ®Google Scholar
• Trabert B, Bauer DC, Buist DSM, et al. Association of circulating progesterone with breast cancer risk among postmenopausal women. JAMA Netw Open. 2020;3(4):e203645.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Bricaire C, De Lignieres B, et al. Oral micronized progesterone. Bioavailability pharmacokinetics, pharmacological and therapeutic implications–a review. Contraception. 1987;36(4):373–402.
   PubMed Web of Science ®Google Scholar
• Wiebe JP, Zhang G, Welch I, et al. Progesterone metabolites regulate induction, growth, and suppression of estrogen-and progesterone receptor-negative human breast cell tumors. Breast Cancer Res. 2013;15(3):R38.
   PubMed Web of Science ®Google Scholar
• Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms–a placebo-controlled randomized trial in healthy postmenopausal women. Menopause. 2012;19(8):886–893.
   PubMed Web of Science ®Google Scholar